Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG

Designation represents progress for patients with suspected Coronary Microvascular Dysfunction as the FDA recognizes disease’s debilitating impacts and the lack of effective non-invasive options for efficient diagnosis

Related Keywords

United States ,Robert Takla ,Timothy Henry ,Odayme Quesada ,Drug Administration ,Christ Hospital Lindner Center ,Christ Hospital Health Network ,European Society Of Cardiology ,Women Heart Center ,Genetesis Inc ,Breakthrough Device ,Christ Hospital ,Medical Director ,Heart Center ,Principal Investigator ,European Society ,Interventional Cardiologist ,Chief Medical Officer ,